费城染色体阳性急性淋巴细胞白血病的靶向治疗
被引量:3
摘要
急性淋巴细胞白血病 (acute lymphoblastic leukemia, ALL)是一种常合并细胞遗传学、分子生物学异常的恶性血液疾病,其中合并费城染色体(Ph)和(或)BCR/ABL(breakpoint cluster region/abelson)融合基因呈阳性的ALL,统称为Ph^+ALL,预后极差。对其采用以酪氨酸激酶抑制剂Imatinib(伊马替尼/格列卫)为代表的靶向治疗联合化疗,目前已成为Ph^+ALL的一线治疗,其缓解率、生存率等均优于单纯化疗,且可提高移植的疗效。
出处
《国际输血及血液学杂志》
CAS
2011年第4期301-304,共4页
International Journal of Blood Transfusion and Hematology
参考文献22
-
1Wassmann B, Pfeifer H, Goekbuget N, et al. Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ALI.). Blood, 2006, 108(5): 1469-1477.
-
2Pfeifer H, Goekbuget N, Volp C, et al. Long-term outcome of 335 adult patients receiving different schedules of imatinib andchemotherapy as front-line treatment for Philadelphia-positive acute lymphoblastie leukemia (Ph + ALl.). Blood, 2010, 116 (21) : 79a.
-
3Thomas I)A, Kantarjian HM, Cortes JE, et al. Outcome after frontline therapy with the hyper-CVAD and imatinib mesylate regimen for adults with de novo or minimally treated Philadelphia (Ph) positive acute lymphoblastic leukemia (ALIA. Proc Am Clin Soc Oncol, 2008, 26:7019a.
-
4de Labarthe A, Rousselot P, Huguet-Rigal F, et al. Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH 2003 study. Blood, 2007, 109(4): 1408-1413.
-
5Yanada M, Sugiura I,Takeuchi J,et al. Japan Adult Leukemia Study Group. Prospective monitoring of BCR-ABL1 transcript levels in patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia undergoing imatinib combined chemotherapy. BrJ Haematol, 2008, 143(4):503-510.
-
6Bassan R, Rossi G, Pogliani EM, et al. Chemotherapy phased imatinib pulses improve long term outcome of adlut patients with Philadelphia chromosome positive acute lymphoblastic leukemia: Northern Italy Leukemia Group Protocol 09/00. J Clin Oncol, 2010, 28(22) : 3644 3652.
-
7Fielding AK, Buck G, Lazarus HM, et al. Imatinib significant enhances long-term outcomes in Philadelphia positive acute lymphoblastic lymphoblastic leukemia; Final results of the UKALL XII/ECOG 2993 trial. Blood, 2010,116(21): 77a.
-
8Lee S, Kim YJ, Min CK, et al. The effect of first line imatinib interim therapy on the outcome of allogeneie stem cell transplantation in adults with newly diagnosed Philadelphia chromosomepositive acute lymphoblastic leukemia. Blood, 2005, 105(9): 3449-3457.
-
9Carpenter PA, Snyder DS, Flowers ME, et al. Prophylactic administration of imatinib after hematopoietie cell transplantation for high risk Philadelphia chromosome positive leukemia. Blood, 2007, 109(7): 2791-2793.
-
10Ottmann OG, Wassmann B, Pfeifer H, et al. Imatinib compared with chemotherapy as frontline treatment of elderly patients with Philadelphia chromosomepositive acute lymphoblastie leukemia (Ph+ALL). Cancer, 2007, 109(10): 2068-2076.
同被引文献62
-
1蒋瑛,高彦荣.甲磺酸伊马替尼治疗骨髓纤维化[J].医学综述,2005,11(2):181-182. 被引量:2
-
2马洪兵,邓承祺.伊马替尼在Ph-的慢性骨髓增殖性疾病中的应用[J].国外医学(输血及血液学分册),2005,28(5):436-438. 被引量:1
-
3Buchdunger E, Zimmermann J, Mett H, et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative [J]. Cancer Res, 1996, 56(1): 100-104.
-
4Druker B J, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells [J]. Nat Med, 1996, 2(5): 561-566.
-
5Deininger MW, Goldman JM, Lydon N, et al. The tyrosine kinase inhibitor CGP 57148B selectively inhibits the growth of BCR-ABL-positive cells [J]. Blood, 1997, 90(9): 3691- 3698.
-
6Carroll M, Ohno-Jones S, Tamura S, et al. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins [J]. Blood, 1997, 90(12): 4947-4952.
-
7Gambacorti-Passerini C, le Coutre P, Mologni L, et al. Inhibition of the ABL kinase activity blocks the proliferation ofBCR/ABL+ leukemic cells and induces apoptosis [J]. Blood Cells Mol Dis, 1997, 23(3): 380-394.
-
8Dan S, Naito M, Tsuruo T. Selective induction of apoptosis in Philadelphia chromosome-positive chronic myelogenous leukemia cells by an inhibitor of BCR-ABL tyrosine kinase, CGP 57148 [J]. Cell Death Differ, 1998, 5(8): 710-715.
-
9Arnold K. After 30 years of laboratory work, a quick approval for STI571 [J]. J Natl Cancer Inst, 2001, 93(13): 972.
-
10Radford IR. Imatinib. Novartis [J]. Curr Opin Investig Drugs, 2002, 3(3): 492-499.
引证文献3
-
1丁倩倩,陈勤奋.甲磺酸伊马替尼的临床应用[J].上海医药,2013,34(3):5-9. 被引量:12
-
2张丽娜,李明会,尹青松,符粤文,周健,宋永平,魏旭东.酪氨酸激酶抑制剂在Ph阳性急性淋巴细胞白血病中的应用[J].中华内科杂志,2015,54(2):139-141. 被引量:1
-
3彭大鹏,魏旭东,米瑞华,尹青松,艾昊,陈琳.达沙替尼治疗费城染色体阳性急性淋巴细胞白血病十例并文献复习[J].白血病.淋巴瘤,2016,25(10):602-606. 被引量:5
二级引证文献18
-
1李渊,王冰洁,刘微,梁赜隐,尹玥,董玉君,王倩,孙玉华,许蔚林,任汉云.达沙替尼联合化疗序贯异基因造血干细胞移植治疗Ph染色体阳性急性淋巴细胞白血病的临床分析[J].中国实验血液学杂志,2020,28(1):18-23. 被引量:6
-
2温伟添.甲磺酸伊马替尼片处方及工艺的研究[J].海峡药学,2014,26(2):27-28. 被引量:2
-
3张阔,陈燕.甲磺酸伊马替尼增加顺铂对耐药卵巢癌细胞作用的研究[J].实用药物与临床,2014,17(9):1096-1099. 被引量:2
-
4王淑华,李泮海,臧恒昌,杨海霞,王秀珍.LC-MS/MS法测定甲磺酸伊马替尼中4-甲基-N-[4-(3-吡啶基)-2-嘧啶基]苯-1,3-二胺[J].中国药师,2014,17(12):2030-2032. 被引量:3
-
5严拯宇,刘新颖,王瑞,廖声华.毛细管气相色谱法测定甲磺酸伊马替尼中残留有机溶剂[J].药学进展,2014,38(10):761-764. 被引量:4
-
6马洪霞,陈蕾,焦雪丽,董秀娟,王娴静,赵晓武.酪氨酸激酶抑制剂治疗慢性粒细胞白血病的临床疗效分析[J].中国实用医药,2016,11(4):118-119. 被引量:2
-
7缪鹏飞,王丹.甲磺酸伊马替尼片处方工艺研究[J].上海医药,2016,37(11):69-73.
-
8柴宇啸,韩毓,王炳,张怡,曲兴龙.伊马替尼治疗晚期恶性黑色素瘤C-kit及B-raf基因突变患者的效果研究[J].中国医院用药评价与分析,2016,16(7):896-899. 被引量:2
-
9陈东奇.槲皮素联合伊马替尼体外抑制人胃癌SNU-1细胞生长和诱导细胞凋亡的研究[J].甘肃中医药大学学报,2017,34(2):27-31. 被引量:6
-
10张倩颖,冯芳.GC-ECD法检测甲磺酸伊马替尼中甲磺酸烷基酯[J].广州化工,2018,46(9):66-68. 被引量:4
-
1刘征辉,薛永权,张学光,夏学鸣,郑列琳,陆廷伟,阮长耿.9例Ph染色体阳性成人急性淋巴细胞白血病的临床和实验研究[J].中华血液学杂志,1995,16(11):575-578. 被引量:8
-
2赵春亭.造血干细胞移植治疗急性髓细胞白血病[J].山东医药,2009,49(13):110-111. 被引量:1
-
3冀冰心,苏力,惠吴函,戴懿,赵弘,徐娟.异基因造血干细胞移植治疗恶性血液病临床分析[J].临床内科杂志,2010,27(10):713-714. 被引量:1
-
4谷月丽.恶性血液疾病患者发生医院感染的影响因素[J].中华实验和临床感染病杂志(电子版),2016,10(3):350-354. 被引量:8
-
5王欢,陈日玲.血管发生与恶性血液病[J].国际病理科学与临床杂志,2008,28(1):37-40.
-
6李萍,梁爱斌.成人急性淋巴细胞白血病的诊疗进展[J].中国癌症杂志,2014,24(10):738-744. 被引量:10
-
7邵蔚,于亚平.ph染色体阳性急性淋巴细胞白血病的研究进展[J].国外医学(输血及血液学分册),2000,23(4):262-265. 被引量:2
-
8何婉,曾小菁.MUC1与恶性血液疾病关系的研究进展[J].国际输血及血液学杂志,2006,29(6):517-520.
-
9许力,李含,莫文健,毛平.减低剂量的地塞米松联合硼替佐米治疗老年多发性骨髓瘤的临床研究[J].临床血液学杂志,2015,28(5):799-800. 被引量:2
-
10罗琳,张克俭,刘尚勤.青年多发性骨髓瘤多处髓外浸润1例[J].临床血液学杂志,2010,23(5):569-571. 被引量:1